Camurus and Braeburn Pharmaceuticals have entered into an exclusive license agreement for Camurus’ weekly and monthly subcutaneous buprenorphine injection products (CAM2038) for the treatment of opioid addiction and pain. Read the full story

The Central Nervous System Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies. Read the full story

Medtronic has completed the acquisition of NGC Medical in a m&a transaction that values NGC at $350 million. Read the full story

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics. Read the full story

Sun Pharmaceutical has announced 6 M&A deals since 2009. Read the full story

Acorda Therapeutics is a commercial stage biopharmaceutical company identifying and developing treatments for neurological disorders including multiple sclerosis, spinal cord injury and disorders of the nervous system.  Read the full story

Acorda Therapeutics, a leading biotechnology company, aims at improving CNS disorders in patients. With its headquarters in the USA, the big biotech company believes in sharing ideas for innovative medical advances. Read the full story

Acorda Therapeutics has announced only 1 M&A deal since 2009.          Read the full story

Alkermes, a fully integrated global biopharma company, is headquartered in Dublin, Ireland. It has emerged as a big biotech company applying the expertise to develop innovative medicines to improve patient outcomes. Its primary therapy focus areas are CNS disorders, such as schizophrenia, addiction and depression. Read the full story

Alkermes is a Dublin based global biopharmaceutical company developing treatments for CNS disorders including schizophrenia, addiction and depression. Read the full story